Literature DB >> 19358496

[Observation on clinical therapeutic effect of Jin's 3-needling therapy on severe autism].

Qing Yuan1, Rui-chao Wang, Zhi-feng Wu, Yan Zhao, Xiao-juan Bao, Rui Jin.   

Abstract

OBJECTIVE: To find out an effective therapy for severe child autism.
METHODS: Sixty-nine autism children were divided into a JIN's 3-needling group (n=35) and a behavior intervention group (n=34). The JIN's needling group was treated with JIN's 3-needling therapy, including Four-shen needling, Zhi-three needling and Nao-three needling, etc. with point group of the head selected as main points; and the behavior intervention group with professional behavior intervention comprehensive therapy in a special training school for autism children. Childhood autism rating scale (CARS) was used for evaluation of therapeutic effects.
RESULTS: After 2 therapeutic courses (240 sessions), the markedly effective rate was 97.1% in the JIN's 3-needling group and 64.7% in the behavior intervention group; there was asignificant difference the therapeutic effect between the two groups (P<0.01); after the first course (first 120 session) and the second course (later 120 sessions), there was a very significant difference between the two groups (P<0.001); and there were significant differences before and after treatment in the courses in the two groups (P<0.01).
CONCLUSION: Both the JIN's 3-needling therapy and the behavior intervention therapy have better therapeutic effects on severe child autism, but the therapeutic effect of JIN's 3-needling is much better.

Entities:  

Mesh:

Year:  2009        PMID: 19358496

Source DB:  PubMed          Journal:  Zhongguo Zhen Jiu        ISSN: 0255-2930


  2 in total

Review 1.  Acupuncture for autism spectrum disorders (ASD).

Authors:  Daniel Kl Cheuk; Virginia Wong; Wen Xiong Chen
Journal:  Cochrane Database Syst Rev       Date:  2011-09-07

2.  Acupuncture for treatment of autism spectrum disorders.

Authors:  Xue Ming; Xiang Chen; Xiao T Wang; Zhen Zhang; Victor Kang; Barbie Zimmerman-Bier
Journal:  Evid Based Complement Alternat Med       Date:  2011-12-06       Impact factor: 2.629

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.